Bart Kiemeney will step down as director of the Radboud Institute for Health Sciences (RIHS) on 1 April. Bart has held this position for over seven years and has brought the quality of science Radboudumc-wide to a higher level. The Board of Directors is very grateful to him for his tireless efforts for high-quality and socially relevant health (care) research.After 1 April Bart will again focus on conducting his own research within his area of expertise and on teaching. We would like to give you the opportunity to say goodbye to Bart as director of the institute during the Radboud Research Round with theme Urological Cancers.
Thursday 28 March 2019
16.00 - 17.00 hrs Radboud Research Round Theme Urological cancers
17.00 - 17.15 hrs Looking back by Paul Smits and Bart Kiemeney
17.15 - 18.30 hrs Research Café
Your presence will be highly appreciated! Please send an e-mail to firstname.lastname@example.org if you want to be present.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology researchers from Radboudumc, Bernhoven Hospital and Jeroen Bosch Hospital described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
Intra-articular corticosteroid injections increase the risk of requiring knee arthroplasty14 May 2020
In The Bone & Joint Journal, RIHS researcher Stan Wijn et al. showed that corticosteroid injections in the knee joint are associated with an increased risk of knee arthroplasty in patients with, or at risk of developing, symptomatic osteoarthritis of the knee.read more
Comenius Senior Fellowship for Jos Kole12 May 2020
Assistant professor in Healthcare Ethics, Jos Kole received a Comenius Senior Fellowship, a prestigious educational scholarship for his plan ‘Physicians with character’. Aim of this scholarship is to innovate the Master of Medicine program.read more
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)12 May 2020
In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.read more
Early symptoms in Radboudumc healthcare workers who were tested for SARS-CoV-212 May 2020
In Eurosurveillance RIHS researcher Alma Tostmann and colleagues from the Radboudumc COVID-19 Team describe that general symptoms like fever, headache, general malaise and muscle ache were associated with a positive SARS-CoV-2 test. Respiratory symptoms however, were not predictive for SARS-CoV-2.read more
Tight controlled dose reduction of biologics in psoriasis patients7 May 2020
Published in JAMA Dermatology, RIHS researcher Selma Atalay and colleagues investigated in a randomized controlled trial a tight controlled dose reduction strategy of the biologics adalimumab, etanercept and ustekinumab in psoriasis patients.read more